Biotechnologie Institut Thurgau an der Universität Konstanz

Publikationen Prof. Dr. Marcus Groettrup

• Li J, Hu S, Johnson HWB, Kirk CJ, Xian P, Song Y, Li Y, Liu N, Groettrup M, Basler M. 2022. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 enables prevention of transplant arteriosclerosis. Cardiovasc Res Dec 4;cvac181. doi: 10.1093/cvr/cvac181. Online ahead of print.
• Del Rio Oliva M, Kirk CJ, Groettrup M, Basler M. 2022. Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome. Eur J Immunol Jun 22. doi: 10.1002/eji.202249851. Online ahead of print.
• Oliveri F, Basler M, Rao TN, Fehling HJ, Groettrup M. 2022. Immunoproteasome Inhibition Reduces the T Helper 2 Response in Mouse Models of Allergic Airway Inflammation. Front Immunol 13:870720. DOI: 10.3389/fimmu.2022.870720
• MacKerracher A, Sommershof A, Groettrup M. 2022. PLGA particle vaccination elicits resident memory CD8 T cells protecting from tumors and infection. Eur J Pharm Sci May 15;175:106209. doi: 10.1016/j.ejps.2022.106209. Online ahead of print
• You H, Mao X, Wang C, Huang G, Groettrup M, Li J. 2022. A Rat Orthotopic Renal Transplantation Model for Renal Allograft Rejection. JoVE Journal of Visualized Experiments 180. - e63464. - JoVE. - eISSN 1940-087X
• Basler M, Groettrup M. 2021. On the Role of the Immunoproteasome in Protein Homeostasis. Cells 10(11):3216. DOI: 10.3390/cells10113216
• Hoefer F, Groettrup M. 2021. Silencing of the proteasome and oxidative stress impair endoplasmic reticulum targeting and signal cleavage of a prostate carcinoma antigen. Biochem Biophys Res Commun Mar 25;554:56-62. doi: 10.1016/j.bbrc.2021.03.023. Online ahead of print.
• Roverato ND, Sailer C, Catone N, Aichem A, Stengel F, Groettrup M. 2021. Parkin is an E3 ligase for the ubiquitin-like modifier FAT10, which inhibits Parkin activation and mitophagy. Cell Rep Mar 16;34(11):108857. doi: 10.1016/j.celrep.2021.108857.
• Basler M, Christ M, Goebel H, Groettrup M. 2021. Immunoproteasome Upregulation Is Not Required to Control Protein Homeostasis during Viral Infection. J Immunol Jan;51(1):138-150. doi: 10.1002/eji.202048646. Epub 2020 Aug 5.
• Held T, Basler M, Knobeloch KP, Groettrup M. 2021. Evidence for an involvement of the ubiquitin-like modifier ISG15 in MHC class I antigen presentation. Eur J Immunol Jan;51(1):138-150. doi: 10.1002/eji.202048646. Epub 2020 Aug 5.
• Koerner J, Horvath D, Herrmann VL, MacKerracher A, Gander B, Yagita H, Rohayem J, Groettrup M. 2021. PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nat Commun May 18;12(1):2935. doi: 10.1038/s41467-021-23244-3.
• Basler M, Groettrup M. 2020. Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy. Genes Immun Aug 25. doi: 10.1038/s41435-020-00109-1. Online ahead of print.
• Boehm AN, Bialas J, Catone N, Sacristan-Reviriego A, van der Spuy J, Groettrup M, Aichem A. 2020. The ubiquitin-like modifier FAT10 inhibits retinal PDE6 activity and mediates its proteasomal degradation. JBC Aug 14;jbc.RA120.013873. doi: 10.1074/jbc.RA120.013873. Online ahead of print.
• Aichem A, Groettrup M. 2020. The ubiquitin-like modifier FAT10 - much more than a proteasome-targeting signal. J Cell Sci Jul 21;133(14):jcs246041.doi: 10.1242/jcs.246041.
• Mah MM, Roverato N, Groettrup M. 2020. Regulation of Interferon Induction by the Ubiquitin-Like Modifier FAT10. Biomolecules Jun 23;10(6):951.doi: 10.3390/biom10060951.
• Schregle R, Mueller S, Legler DF, Rossy J, Krueger WA, Groettrup M. 2020. FAT10 localizes in dendritic cell aggresome-like induced structures and contributes to their disassembly. J Cell Sci Jun 16:jcs.240085. doi: 10.1242/jcs.240085. Online ahead of print.
• Pawar A, Basler M, Goebel H, Alvarez Salinas GO, Groettrup M, Böttcher T. 2020. Competitive Metabolite Profiling of Natural Products Reveals Subunit Specific Inhibitors of the 20S Proteasome. J Immunol ACS Central Science ; 2020. - American Chemical Society (ACS). - ISSN 2374-7943. - eISSN 2374-7951.
• Basler M, Claus M, Klawitter M, Goebel H, Groettrup M. 2019. Immunoproteasome Inhibition Selectively Kills Human CD14+ Monocytes and as a Result Dampens IL-23 Secretion. J Immunol 203(7):1776-1785. doi: 10.4049/jimmunol.1900182. Epub 2019 Sep 4.
• Schmidtke G, Schregle R, Alvarez G, Huber EM, Groettrup M. 2019. The 20S immunoproteasome and constitutive proteasome bind with the same affinity to PA28αβ and equally degrade FAT10. Mol Immunol Sep;113:22-30. doi: 10.1016/j.molimm.2017.11.030. Epub 2017 Dec 6.
• Aichem A, Sailer C, Ryu S, Catone N, Stankovic-Valentin N, Schmidtke G, Melchior F, Stengel F, Groettrup M. 2019. The ubiquitin-like modifier FAT10 interferes with SUMO activation. Nat Commun Oct 1;10(1):4452. doi: 10.1038/s41467-019-12430-z.
• Koerner J, Horvath D, Groettrup M. 2019. Harnessing Dendritic Cells for Poly (D,L-lactide-co-glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy. Front Immunol Apr 5;10:707. doi: 10.3389/fimmu.2019.00707. eCollection 2019.
• Mah MM, Basler M, Groettrup M. 2019. The ubiquitin-like modifier FAT10 is required for normal IFN-γ production by activated CD8+ T cells. Mol Immunol Apr;108:111-120. doi: 10.1016/j.molimm.2019.02.010. Epub 2019 Feb 25.
• Basler M, Groettrup M. 2019. Testing the Impact of Protease Inhibitors in Antigen Presentation Assays. Methods Mol Biol 1988:59-69. doi: 10.1007/978-1-4939-9450-2_5.
• Bialas J, Boehm AN, Catone N, Aichem A, Groettrup M. 2019. The ubiquitin-like modifier FAT10 stimulates the activity of the deubiquitylating enzyme OTUB1. J Biol Chem Feb 4. pii: jbc.RA118.005406. doi: 10.1074/jbc.RA118.005406. [Epub ahead of print].
• Aichem A, Boehm AN, Catone N, Schmidtke G, Groettrup M. 2019. Analysis of modification and proteolytic targeting by the ubiquitin-like modifier FAT10. Methods Enzymol 618:229-256. doi: 10.1016/bs.mie.2018.12.040. Epub 2019 Feb 83.
• Li J, Koerner J, Basler M, Brunner T, Kirk CJ, Groettrup M. 2019. Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors. Kidney Int Jan 22. pii: S0085-2538(18)30823-8. doi: 10.1016/j.kint.2018.10.022. [Epub ahead of print].
• Basler M, Li J, Groettrup M. 2019. On the role of the immunoproteasome in transplant rejection. Immunogenetics Sep 15. doi: 10.1007/s00251-018-1084-0. [Epub ahead of print].
• Gutbier S, Spreng AS, Delp J, Schildknecht S, Karreman C, Suciu I, Brunner T, Groettrup M, Leist M. 2018. Prevention of neuronal apoptosis by astrocytes through thiol-mediated stress response modulation and accelerated recovery from proteotoxic stress. Cell Death Differ Dec;25(12):2101-2117. doi: 10.1038/s41418-018-0229-x. Epub 2018 Nov 2.
• Schmidt C, Berger T, Groettrup M, Basler M. 2018. Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis. Front Immunol Oct 26;9:2386. doi: 10.3389/fimmu.2018.02386. eCollection 2018.
• Basler M, Lindstrom MM, LaStant JJ, Bradshaw JM, Owens TD, Schmidt C, Maurits E, Tsu C, Overkleeft HS, Kirk CJ, Langrish CL, Groettrup M. 2018. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. EMBO Rep Oct 2. pii: e46512. doi: 10.15252/embr.201846512. [Epub ahead of print].
• Aichem A, Anders S, Catone N, Rößler P, Stotz S, Berg A, Schwab R, Scheuermann S, Bialas J, Schütz-Stoffregen MC, Schmidtke G, Peter C, Groettrup M, Wiesner S. 2018. The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation. Nat Commun Aug 20;9(1):3321. doi: 10.1038/s41467-018-05776-3.
• Treise I, Huber EM, Klein-Rodewald T, Heinemeyer W, Grassmann SA, Basler M, Adler T, Rathkolb B, Helming L, Andres C, Klaften M, Landbrecht C, Wieland T, Strom TM, McCoy KD, Macpherson AJ, Wolf E, Groettrup M, Ollert M, Neff F, Gailus-Durner V, Fuchs H, Hrabě de Angelis M, Groll M, Busch DH. 2018. Defective immuno- and thymoproteasome assembly causes severe immunodeficiency. Sci Rep Apr 13;8(1):5975. doi: 10.1038/s41598-018-24199-0.
• Schregle R, Mah MM, Mueller S, Aichem A, Basler M, Groettrup M. 2018. The expression profile of the ubiquitin-like modifier FAT10 in immune cells suggests cell type-specific functions. Immunogenetics Mar 5. doi: 10.1007/s00251-018-1055-5. [Epub ahead of print].
• Basler M, Mundt S, Groettrup M. 2018. The immunoproteasome subunit LMP7 is required in the murine thymus for filling up a hole in the T cell repertoire. Eur J Immunol 48(3):419-429.
• Basler M, Maurits E, de Bruin G, Koerner J, Overkleeft HS, Groettrup M. 2018. Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome. Br J Pharmacol 175(1):38-52. doi: 10.1111/bph.14069. Epub 2017 Nov 29.
• Li J, Basler M, Alvarez G, Brunner T, Kirk CJ, Groettrup M. 2018. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation. Kidney Int 93(3):670-680.
• Schmidtke G, Schregle R, Alvarez G, Huber EM, Groettrup M. 2017. The 20S immunoproteasome and constitutive proteasome bind with the same affinity to PA28αβ and equally degrade FAT10. Mol Immunol Dec 2. pii: S0161-5890(17)30593-X. doi: 10.1016/j.molimm.2017.11.030. [Epub ahead of print].
• Sommershof A, Scheuermann L, Körner J, Groettrup M. 2017. Chronic stress suppresses anti-tumor TCD8+ responses and tumor regression following cancer immunotherapy in a mouse model of melanoma. Brain Behav Immun 65:140-149.
• Mundt S, Basler M, Sawitzki B, Groettrup M. 2017. No prolongation of skin allograft survival by immunoproteasome inhibition in mice. Mol Immunol 88:32-37.
• Bitzer A, Basler M, Krappmann D, Groettrup M. 2017. Immunoproteasome subunit deficiency has no influence on the canonical pathway of NF-κB activation. Mol Immunol. 83:147-53.
• Koerner J, Brunner T, Groettrup M. 2017. Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice. Oncotarget. in press.
• Spinnenhirn V, Bitzer A, Aichem A, Groettrup M. 2016. Newly translated proteins are substrates for ubiquitin, ISG15 and FAT10. FEBS Lett. doi: 10.1002/1873-3468.12512. [Epub ahead of print].
• Rank L, Veith S, Gwosch EC, Demgenski J, Ganz M, Jongmans MC, Vogel C, Fischbach A, Buerger S, Fischer JM, Zubel T, Stier A, Renner C, Schmalz M, Beneke S, Groettrup M, Kuiper RP, Bürkle A, Ferrando-May E, Mangerich A. 2016. Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells. Nucl Acids Res. Sep 29. pii: gkw859. [Epub ahead of print].
• Aichem A, Groettrup M. 2016. The ubiquitin-like modifier FAT10 in cancer development. Int J Biochem Cell Biol. Jul 5. pii: S1357-2725(16)30165-0. doi: 10.1016/j.biocel.2016.07.001. [Epub ahead of print]
• Mulder M, Witting K, Berlin I, Pruneda JN, Wu KP, Chang JG, Merkx R, Bialas J, Groettrup M, Vertegal AC, Schulman BA, Komander D, Neefjes J, El Oualid F, Ovaa H. 2016. A cascading activity-based probe sequentially targets E1-E2-E3 ubiquitin enzymes. Nature Chem Biol 12:523-530
• Mundt S, Basler M, Buerger S, Engler H, Groettrup M. 2016. Inhibiting the immunoproteasome exacerbates the pathogenesis of systemic Candida albicans infection in mice. Scientific Reports in press.
• Herrmann VL, Wieland DE, Legler DF, Wittmann V, Groettrup M. 2016. The STEAP1262-270 peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice-a new approach to immunotherapy against prostate carcinoma. Prostate 75:456-468.
• Bitzer A, Basler M, Groettrup M. 2016. Chaperone BAG6 is dispensable for MHC class I antigen processing and presentation. Mol Immunol Jan;69:99-105. doi: 10.1016/j.molimm.2015.11.004. Epub 2015 Nov 17.
• Mundt S, Engelhardt B, Kirk CJ, Groettrup M,Basler M. 2016. Inhibition and deficiency of the immunoproteasome subunit LMP7 attenuates LCMV-induced meningitis. Eur J Immunol Jan;46(1):104-13. doi: 10.1002/eji.201545578. Epub 2015 Nov 2.
• Basler M, Mundt S, Bitzer A, Schmidt C, Groettrup M. 2015. The immunoproteasome: a novel drug target for autoimmune diseases. Clin Exp Rheumatol Jul-Aug;33(4 Suppl 92):S74-9. Epub 2015 Oct 12.
• Buerger S, Herrmann VL, Mundt S, Trautwein N, Groettrup M, Basler M. 2015. The Ubiquitin-like Modifier FAT10 Is Selectively Expressed in Medullary Thymic Epithelial Cells and Modifies T Cell Selection. J Immunol Sep 23. pii: 1500592. [Epub ahead of print].
• Basler M, Buerger S, Groettrup M. 2015. The ubiquitin-like modifier FAT10 in antigen processing and antimicrobial defense. Mol Immunol May 13. pii: S0161-5890(15)00371-5. doi: 10.1016/j.molimm.2015.04.012. [Epub ahead of print].
• Dufner A, Kisser A, Niendorf S, Basters A, Reissig S, Schönle A, Aichem A, Kurz T, Schlosser A, Yablonski D, Groettrup M, Buch T, Waisman A, Schamel WW, Prinz M, Knobeloch KP. 2015. The ubiquitin-specific protease USP8 is critical for the development and homeostasis of T cells. Nature Immunol. Jul 27. doi: 10.1038/ni.3230.
• Mundt S, Groettrup M, Basler M. 2015. Analgesia in mice with experimental meningitis reduces pain without altering immune parameters. ALTEX Mar 24. doi: http://dx.doi.org/10.14573/altex.1502021. [Epub ahead of print].
• Bialas J, Groettrup M, Aichem A. 2015. Conjugation of the Ubiquitin Activating Enzyme UBE1 with the Ubiquitin-Like Modifier FAT10 Targets It for Proteasomal Degradation. PLoS One. Mar 13;10(3):e0120329. doi: 10.1371/journal.pone.0120329. eCollection 2015.
• Erath S, Groettrup M. 2015. No evidence for immunoproteasomes in chicken lymphoid organs and activated lymphocytes. Immunogenetics 19 Nov 2014, pulished online.
• Groettrup M, Ovaa H. 2014. Editorial overview: Molecular immunology: targeting the immune system. Curr Opin Chem Biol Dec;23:v-vii.
• Kisselev AF, Groettrup M. 2014. Subunit specific inhibitors of proteasomes and their potential for immunomodulation. Curr Opin Chem Biol Sep 15;23C:16-22.
• Spinnenhirn V, Farhan H, Basler M, Aichem A, Canaan A, Groettrup M. 2014. The ubiquitin-like modifier FAT10 decorates autophagy targeted Salmonella and contributes to resistance of mice. J Cell Sci Sep 30. pii: jcs.152371. [Epub ahead of print].
• Morath J, Gola H, Sommershof A, Hamuni G, Kolassa S, Catani C, Adenauer H, Ruf-Leuschner M, Schauer M, Elbert T, Groettrup M, Kolassa IT. 2014. The effect of trauma-focused therapy on the altered T cell distribution in individuals with PTSD: evidence from a randomized controlled trial.J Psychiatr Res 2014 Jul;54:1-10. in process
• Aichem A, Catone N, Groettrup M. 2014. Investigations into the auto-FAT10ylation of the bispecific E2 conjugating enzyme USE1.FEBS J doi: 10.1111/febs.12745. [Epub ahead of print].
• Schmidtke G, Aichem A, Groettrup M. 2014. FAT10ylation as a signal for proteasomal degradation. Biochim Biophys Acta Mol Cell Res 1843(1):97-102.
• Kniepert A, Groettrup M. 2014. The unique functions of tissue-specific proteasomes. Trends Biochem Sci 39(1):17-24.
• Basler M, Mundt S, Muchamuel T, Moll C, Jiang J, Groettrup M, Kirk CJ. 2014. Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med 6(2):226-238.
• Nathan JA, Spinnenhirn V, Schmidtke G, Basler M, Groettrup M, Goldberg AL. 2013. Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 152(5):1184-1194.
• Basler M, Groettrup M. 2013. Using protease inhibitors in antigen presentation assays. Methods Mol Biol 960:31-39.
• Gola H, Engler H, Sommershof A, Adenauer H, Kolassa S, Schedlowski M, Groettrup M, Elbert T, Kolassa IT. 2013. Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells. BMC Psychiatry 13:40. doi: 10.1186/1471-244X-13-40.
• Basler M, Kirk CJ, Groettrup M. 2013. The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol 25(1):74-80.
• Mahmutefendic H, Zagorac GB, Tomaš MI, Groettrup M, Momburg F, Lucin P. 2013. Endosomal trafficking of open Major Histocompatibility Class I conformers-Implications for presentation of endocytosed antigens. Mol Immunol 55(2):149-152.
• Richet E, Pooler AM, Rodriguez T, Novoselow SS, Schmidtke G, Groettrup M, Hanger DP, Cheetham ME, van der Spuy J. 2012. NUB1 modulation of GSK3ß reduces tau aggregation. Hum Mol Genet 21(24):5254-5267.
• Kalim KW, Groettrup M. 2013. Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit. Mol Immunol 53(3):274-282.
• Kalim KW, Basler M, Kirk CJ, Groettrup M. 2012. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol 189(8):4182-4193.
• Basler M, Lauer C, Moebius J, Weber R, Przybylski M, Kisselev AF, Tsu C, Groettrup M. 2012. Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation. J Immunol 189(4):1868-1877.
• Schliehe C, Bitzer A, van den Broek M, Groettrup M. 2012. Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo. J Virol 86(18):9782-9793.
• Mueller M, Reichardt W, Koerner J, Groettrup M. 2012. Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice. J Control Release 162(1):159-166.
• Aichem A, Kalveram B, Spinnenhirn V, Kluge K, Catone N, Johansen T, Groettrup M. 2012. The proteomic analysis of FAT10 substrates identifies p62/SQSTM1 as a substrate of FAT10ylation. J Cell Sci 125(19):4576-4585.
• Schaeuble K, Hauser MA, Rippl AV, Bruderer R, Otero C, Groettrup M, Legler DF. 2012. Ubiquitylation of the chemokine receptor CCR7 enables efficient receptor recycling and cell migration. J Cell Sci 125(19):4463-4474.
• Bett JS, Kanuga N, Richet E, Schmidtke G, Groettrup M, Cheetham ME, van der Spuy J. 2012. The Inherited Blindness Protein AIPL1 Regulates the Ubiquitin-Like FAT10 Pathway. PLoS One 7(2):e30866. Epub 2012 Feb 7.
• Aichem A, Groettrup M. 2012. Detection and analysis of FAT10 modification. Methods Mol Biol 832:125-32.
• Basler M, Groettrup M. 2012. Immunoproteasome-specific inhibitors and their application. Methods Mol Biol 832:391-401.
• Rani N, Aichem A, Schmidtke G, Kreft S, Groettrup M. 2012. FAT10 and NUB1L bind to the VWA domain of Rpn10 and Rpn1 to enable proteasome-mediated proteolysis. Nature Comm 3:749.
• Huber EM*, Basler M*, Schwab R*, Kirk CJ, Heinemeyer W, Groettrup M, Groll M. 2012. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 148(4):727-38. * These authors contributed equally to this work
• Spies E, Reichardt W, Alvarez G, Groettrup M, Oehlschlaeger P. 2012. An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma. Mol Ther 20(3):555-564.
• Basler M, Moebius J, Beck U, Kirk CC, Groettrup M. 2011. The antiviral immune response in mice devoid of immunoproteasome activity. J Immunol 187(11):5548-5557.
• Schaeuble K, Hauser MA, Singer E, Groettrup M, Legler DF. 2011. Cross-talk between TCR and CCR7 signaling sets a temporal threshold for enhanced T lymphocyte migration. J Immunol 187(11):5645-5652.
• Schliehe C, Redaelli C, Engelhardt S, Fehlings M, Mueller M, van Rooijen N, Thiry M, Hildner K, Weller H, Groettrup M. 2011. CD8- dendritic cells and macrophages cross-present poly(D,L-lactate-co-glycolate) acid microsphere-encapsulated antigen in vivo. J Immunol 187(5):2112-2121.
• Schliehe C, Schliehe C, Thiry M, Tromsdorf UI, Hentschel J, Weller H, Groettrup M. 2011. Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy. J Controlled Release 151(3):278-285.
• Mueller M, Schlosser E, Gander B, Groettrup M. 2011. Tumor eradication by immunotherapy with biodegradable PLGA microspheres - an alternative to incomplete Freund´s adjuvant. Int J Cancer 129(2):407-416.
• Sommershof A, Basler M, Riether C, Engler H, Groettrup M. 2011. Attenuation of the cytotoxic T lymphocyte response to lymphocytic choriomeningitis virus in mice subjected to chronic social stress. Brain Behav Immun 25(2):340-348.
• Moebius J, Van den Broek M, Groettrup M, Basler M. 2010. Immunoproteasomes are essential for survival and expansion of T cells in virus infected mice. Eur J Immunol 40(12):3439-3449.
• Kremer M, Henn A, Kolb C, Basler M, Moebius J, Guillaume B, Leist M, Van Den Eynde BJ, Groettrup M. 2010. Reduced immunoproteasome formation and accumulation of immunoproteasomal percursors in the brain of lymphocytic choriomeningitis virus-infected mice. J Immunol 185(9):5549-5560.
• Basler M, Dajee M, Moll C, Groettrup M, Kirk CJ. 2010. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome1. J Immunol 185(1):634-641.
• Aichem A, Pelzer C, Lukasiak S, Kalveram B, Sheppard PW, Rani N, Schmidtke G, Groettrup M. 2010. USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10 which FAT10ylates itself in cis. Nat Commun 1(2):1-10.
• Ohlschlager P, Spies E, Alvarez G, Quetting M, Groettrup M. 2010. The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer 128(2):473-481.
• Groettrup M, Kirk CJ, Basler M. 2010. Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol 10(1):73-78.
• Sommershof A, Aichinger H, Engler H, Adenauer H, Catani C, Boneberg EM, Elbert T, Groettrup M, Kolassa IT. 2009. Substantial reduction of naïve and regulatory T cells following traumatic stress. Brain Behav Immun 23(8):1117-1124.
• Basler M, Lauer C, Beck U, Groettrup M. 2009. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 183(10):6145-6150.
• Muchamuel T*, Basler M*, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, Groettrup M. 2009. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15(7):781-787. * shared first authorship
• Fischer S, Schlosser E, Mueller M, Csaba N, Merkle HP, Groettrup M, Gander B. 2009. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J Drug Target 17(8):652-661.
• Schmidtke G, Kalveram B, Groettrup M. 2009. Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L. FEBS Lett 583(3):591-594.
• Krause P, Bruckner M, Uermoesi C, Singer C, Groettrup M, Legler DF. 2009. Prostaglandin E2 enhances T cell proliferation by inducing the costimulatory molecules OX40L, CD70 and 4-1BBL on dendritic cells. Blood 113(11):2451-2460.
• Kalveram B, Schmidtke G, Groettrup M. 2008. The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition. J Cell Sci 121(24):4079-4088.
• Lukasiak S, Schiller C, Oehlschlaeger P, Schmidtke G, Krause P, Legler DF, Autschbach F, Schirmacher P, Breuhahn K, Groettrup M. 2008. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 27(46):6068-6074.
• Schmidtke G, Groettrup M. 2008. Identification of homozygous transgenic mice by genomic real-time PCR. Meth Mol Biol 429:45-58.
• Lukasiak S, Breuhahn K, Schiller C, Schmidtke G, Groettrup M. 2008. Quantitative analysis of gene expression relative to 18S rRNA in carcinoma samples using the LightCycler instrument and a SYBR GreenI-based assay: determining FAT10 mRNA levels in hepatocellular carcinoma. Meth Mol Biol 429:59-72.
• Otero C, Eisele PS, Schaeuble K, Groettrup M, Legler DF. 2008. Distinct motifs in the chemokine receptor CCR7 regulate signal transduction, receptor trafficking and chemotaxis. J Cell Sci 121(16):2759-2767.
• Groettrup M, Pelzer C, Schmidtke G, Hofmann K. 2008. Activating the ubiquitin family: UBA6 challenges the field. Trends Biochem Sci 33(5):230-237.
• Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B, Groettrup M. 2008. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26(13):1626-1637.
• Schlosser E, Otero C, Wünsch C, Kessler BM, Edelmann M, Brunisholz R, Drexler I, Legler DF*, Groettrup M*. 2007. A novel cytosolic class I antigen-processing pathway for endoplasmic-reticulum-targeted proteins. EMBO Rep 8(10):945-951. * share senior authorship
• Krause P, Singer E, Darley PI, Klebensberger J, Groettrup M, Legler DF. 2007. Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leuk Biol 82(5):1106-1114.
• Pelzer C, Kassner I, Matentzoglu K, Singh RK, Wollscheid HP, Scheffner M, Schmidtke G, Groettrup M. 2007. UBE1L2, a novel E1 enzyme specific for ubiquitin. J Biol Chem 282(32):23010-23014.
• Basler M, Groettrup M. 2007. No essential role for tripeptidyl peptidase II for the processing of LCMV-derived T cell epitopes. Eur J Immunol 37(4):896-904.
• Basler M, Groettrup M. 2007. Advances in prostate cancer immunotherapies. Drugs Aging 24(3):197-221.
• Mazza F, Tronconi E, Valerio A, Groettrup M, Kremer M, Tossi A, Benedetti F, Cargnel A, Atzori C. 2006. The non-peptidic HIV protease inhibitor Tipranavir and two synthetic peptidomimetics (TS98 and TS102) modulate pneumocystis carinii growth and proteasome activity of HEL299 cell line. J Eukaryot Microbiol 53:S144–S146.
• Fischer S, Uetz-von Allmen E, Waeckerle-Men Y, Groettrup M, Merkle HP, Gander B. 2007. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 28:994-1004.
• Otero C, Groettrup M, Legler D. 2006. Opposite fate of endocytosed CCR7 and its ligands: recycling versus degradation. J Immunol 177:2314-2323.
• Basler M, Moebius J, Elenich L, Groettrup M, Groettrup M, Monaco JJ. 2006. An altered T cell repertoire in MECL-1-deficient mice. J Immunol 176:6665-6672.
• Schmidtke G, Kalveram B, Weber E, Bochtler P, Lukasiak S, Hipp MS, Groettrup M. 2006. The UBA domains of NUB1L are required for binding but not for accelerated degradation of the ubiquitin-like modifier FAT10. J Biol Chem 281:20045-20054.
• Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Boehme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S. 2006. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 55(12):1524-33. Epub 2006 Apr 13
• Legler DF, Krause P, Scandella E, Singer E, Groettrup M. 2006. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol 176:966-973.
• Waeckerle-Men Y, Uetz-von Allmen E, Gander B, Scandella E, Schlosser E, Schmidtke G, Merkle HP, Groettrup M. 2006. Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 24(11):1847-1857.
• Alvarez G, De Giuli R, Kolb C, Groettrup M. 2005. A rapid method to determine the activities of proteasomes and immunoproteasomes. MACS & more 9:4-7.
• Basta S, Stoessel R, Basler M, van den Broek M, Groettrup M. 2005. Cross-Presentation of the long-lived Lymphocytic Choriomeningitis Virus Nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J Immunol 175:796-805.
• Hipp MS, Kalveram B, Raasi S, Groettrup M, Schmidtke G. 2005. FAT10 - a ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol 25:3483-3491.
• Waeckerle-Men Y, Uetz-von Allmen E, von Moos R, Classon BJ, Scandella E, Schmid HP, Ludewig B, Groettrup M, Gillessen S. 2005. Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T- cell stimulation. Prostate 64(4):323-331.
• Waeckerle-Men Y, Gander B, Groettrup M. 2005. Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Methods Mol Med 109:35-46.
• Waeckerle-Men Y, Groettrup M. 2005. PLGA microspheres for an improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Delivery Rev 57:475-482.
• Groettrup M, de Giuli R, Schmidtke G. 2004. Effects of the HIV-1 protease inhibitor Ritonavir on proteasome activity and antigen presentation. In Adams, J.: Proteasome inhibitors in cancer therapy Humana Press, Totowa, NJ., in the press
• Basler M, Youhnovski N, van den Broek M, Przybylski M, Groettrup M. 2004. Immunoproteasomes downregulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J Immunol 173:3925-3934.
• Waeckerle-Men Y, Scandella E, Uetz-von Allmen E, Ludewig B, Gillessen S, Merkle HP, Gander B, Groettrup M. 2004. Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable PLGA microspheres for DC-vaccination. J Immunol Methods 287:109-124.
• Hipp MS, Raasi S, Groettrup M, Schmidtke G. 2004. NEDD8 ultimate buster-1L interacts with the ubiquitin-like protein FAT10 and accelerates its degradation. J Biol Chem 279:16503-16510.
• Scandella E, Men Y, Gillessen S, Prikler L, Groettrup M. 2004. CCL19/CCL21 triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 103:1595-1601.
• Khan S, Zimmermann A, Basler M, Groettrup M, Hengel H. 2004. A cytomegaloviral inhibitor of IFN-gamma signaling controls immunoproteasome assembly. J Virol 78:1831-1842.
• Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. 2003. CCL19/21-induced migration of monocyte-derived dendritic cells requires PGE2. MACS & more 7:14-15.
• Froeschke M, Basler M, Groettrup M, Dobberstein B. 2003. Long-lived signal peptide of lymphocytic choriomeningitis virus glycoprotein pGP-C. J Biol Chem 278:41914-41920.
• Gillessen S, Groettrup M, Cerny T. 2003. Proteasomes, a new target for cancer therapy. Onkologie 25:534-539.
• Audran R, Peter K, Dannull J, Men Y, Groettrup M, Gander B, Corradin G. 2002. Micro-encapsulation of peptides prolongs their presentation to cytotoxic T cells by antigen presenting cells in vitro. Vaccine 21:1250-1255.
• Scandella E, Men Y, Gillessen S, Förster R, Groettrup M. 2002. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100:1354-1361.
• Groettrup M, van den Broek M, Schwarz K, Macagno A, Khan S, de Giuli R, Schmidtke G. 2001. Structural plasticity of the proteasome and its function in antigen processing. Crit Rev Immunol 21:339-359.
• Khan S, van den Broek M, Schwarz K, de Giuli R, Diener PA, Groettrup M. 2001. Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J Immunol 167:6859-6868.
• Khan S, de Giuli R, Schmidtke G, Bruns M, Buchmeier M, van den Broek M, Groettrup M. 2001. Cutting Edge: Neosynthesis is required for the presentation of a T cell epitope from a long lived viral protein. J Immunol 167:4801-4804.
• Macagno A, Kuehn L, de Giuli R, Groettrup M. 2001. Pronounced upregulation of the PA28α/β proteasome regulator but little increase in the steady state content of immunoproteasomes during dendritic cell maturation. Eur J Immunol 31:3271-3280.
• Raasi S, Schmidtke G, Groettrup M. 2001. The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J Biol Chem 276:35334-35343.
• Moradpour D, Grabscheid B, Kammer AR, Schmidtke G, Groettrup M, Blum HE, Cerny A. 2001. Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation in vitro. Hepatology 33:1282-1287.
• Groettrup M, Khan S, Schwarz K, Schmidtke G. 2001. Interferon-γ inducible exchanges of 20S proteasome active site subunits: Why? Biochimie 83:367-372.
• Limmer A, Ohl J, Kurts C, Ljungren HG, Reiss Y, Groettrup M, Momburg F, Arnold B, Knolle PA. 2000. Efficient presentation of exogenous antigen by liver endothelial cells to CD8⁺ T cells results in antigen-specific T-cell tolerance. Nature Med 6:1348-1354.
• Schwarz K, Eggers M, Soza A, Koszinowski UH, Kloetzel PM, Groettrup M. 2000. The proteasome regulator PA28α/β can enhance antigen presentation without affecting 20S proteasome subunit composition. Eur J Immunol 30:3672-3679.
• Dannull J, Cerny T, Ackermann DK, Groettrup M. 2000. Current status of dendritic cell-based tumor vaccination. Onkologie 23:544-551.
• Dannull J, Diener PA, Prickler L, Fürstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M. 2000. Prostate stem cell antigen (PSCA) is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 60:5522-5528.
• Schwarz K, van den Broek M, Kostka S, Kraft R, Soza A, Schmidtke G, Kloetzel PM, Groettrup M. 2000. Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1 but not PA28α/β enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. J Immunol 165:768-778.
• Schmidtke G, Emch S, Groettrup M, Holzhütter HG. 2000. Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20S proteasome. J Biol Chem 275:22056-22063.
• Schwarz K, de Giuli R, Schmidtke G, Kostka S, van den Broek M, Kim KB, Crews CM, Kraft R, Groettrup M. 2000. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or downregulate antigen presentation at nontoxic doses. J Immunol 164:6147-6157.
• Schwarz K, van den Broek M, de Giuli R, Seelentag WW, Shastri N, Groettrup M. 2000. The use of LCMV-specific T cell hybridomas for the quantitative analysis of MHC class I restricted antigen presentation. J Immunol Methods 237:199-202.
• Schmidtke G, Holzhütter HG, Bogyo M, Kairies N, Groll M, de Giuli R, Groettrup M. 1999. How an inhibitor of the HIV-1 protease modulates proteasome activity. J Biol Chem 274:35734-35740.
• Groettrup M, Schmidtke G. 1999. Intracellular processing of viral and tumour antigens by proteasomes. Schweiz Med Wochenschr 129:1660-1665.
• Raasi S, Schmidtke G, de Giuli R, Groettrup M. 1999. A ubiquitin-like protein which is synergistically inducible by interferon-γ and tumor necrosis factor-α. Eur J Immunol 29:4037-4042.
• Macagno A, Gilliet M, Sallusto F, Lanzavecchia A, Nestle FO, Groettrup M. 1999. Dendritic cells upregulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur J Immunol 29:4030-4036.
• Groettrup M, Schmidtke G. 1999. Selective proteasome inhibitors: modulators of antigen presentation? Drug Discovery today 4:63-71.
• André P, Groettrup M, Klenerman P, de Giuli R, Booth Jr. BL, Cerundolo V, Bonneville M, Jotereau F, Zinkernagel RM, Lotteau V. 1998. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 95:13120-13124.
• Gallimore A, Schwarz K, van den Broek M, Hengartner H, Groettrup M. 1998. The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope. Mol Immunol 35:581-591.
• Schmidtke G, Eggers M, Ruppert T, Groettrup M, Koszinowski UH, Kloetzel PM. 1998. Inactivation of a defined active site in the mouse 20S proteasome complex enhances MHC class I antigen presentation of a mouse cytomegalovirus protein. J Exp Med 187:1641-1646.
• Groettrup M, Standera S, Stohwasser R, Kloetzel PM. 1997. The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proc Natl Acad Sci USA 94:8970-8975.
• Soza A, Groettrup M, Henklein P, Tanaka K, Kloetzel PM. 1997. Expression and subcellular localization of mouse 20S proteasome PA28 regulator. FEBS Lett 406:27-34.
• Stohwasser R, Standera S, Peters I, Kloetzel PM, Groettrup M. 1997. Molecular cloning of the mouse proteasome subunts MC14 and MECL-1: reciprocally regulated tissue expression of interferon-γ-modulated proteasome subunits. Eur J Immunol 27:1182-1187.
• Dick TP, Ruppert T, Groettrup M, Kloetzel PM, Kuehn L, Koszinowski UH, Stevanovic S, Schild H, Rammensee H. 1996. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 86:253-262.
• Ossendorp F, Eggers M, Neisig A, Ruppert T, Groettrup M, Sijts A, Mengedé E, Kloetzel PM, Neefjes J, Koszinowski UH, Melief C. 1996. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity 5:115-124.
• Groettrup M, Soza A, Kuckelkorn U, Kloetzel PM. 1996. Peptide antigen production by the proteasome: complexity provides efficiency. Immunol Today 17:429-435.
• Rotem-Yehudar R, Groettrup M, Soza A, Kloetzel PM, Ehrlich R. 1996. LMP-associated proteolytic activities and TAP-dependent transport for class I MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J Exp Med 183:499-514.
• Groettrup M, Soza A, Eggers M, Kuehn L, Dick TP, Schild H, Rammensee HG, Koszinowski UH, Kloetzel PM. 1996. A role for the proteasome regulator PA28α in antigen presentation. Nature 381:166-168.
• Groettrup M, Kraft R, Kostka S, Standera S, Stohwasser R, Kloetzel PM. 1996. A third interferon-γ-induced subunit exchange in the 20S proteasome. Eur J Immunol 26:863-869.
• Kuckelkorn U, Frentzel S, Kraft R, Kostka S, Groettrup M, Kloetzel PM. 1995. Incorporation of major histocompatibility complex - encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-γ. Eur J Immunol 25:2605-2611.
• Groettrup M, Ruppert T, Kuehn L, Seeger M, Standera S, Koszinowski UH, Kloetzel PM. 1995. The interferon-γ-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20S proteasome in vitro. J Biol Chem 270:23808-23815.
• Saint-Ruf C, Ungewiss K, Groettrup M, Bruno L, Fehling HJ, von Boehmer H. 1994. Analysis and expression of a cloned pre - T cell receptor gene. Science 266:1208-1212.
• Groettrup M, von Boehmer H. 1993. A role for a pre - T cell receptor in T - cell development. Immunol Today 14:610-614.
• Groettrup M, Ungewiss K, Azogui O, Palacios R, Owen MJ, Hayday AC, von Boehmer H. 1993. A novel disulfide-linked heterodimer on pre - T cells consists of the T cell receptor β chain and a 33 kD glycoprotein. Cell 75:283-294.
• Bernard O, Groettrup M, Mugneret F, Berger R, Azogui O. 1993. Molecular analysis of T cell receptor transcripts in a human T cell leukemia bearing a t(1;14) and an inv(7); cell surface expression of a TCR-β chain in the absence of α chain. Leukemia 7:1645-1653.
• Groettrup M, von Boehmer H. 1993. T cell receptor β chain dimers on immature thymocytes from normal mice. Eur J Immunol 23:1393-1396.
• Groettrup M, Baron A, Griffiths G, Palacios R, von Boehmer H. 1992. T cell receptor (TCR) β chain homodimers on the surface of immature but not mature α,γ,δ chain deficient T cell lines. EMBO J 11:2735-2746.
• Pircher H, Rabaï N, Groettrup M, Grégoire C, Speiser DE, Happ MP, Palmer E, Zinkernagel RM, Hengartner H, Malissen B. 1992. Preferential positive selection of Vα2⁺CD8⁺ T cells in mouse strains expressing both H-2^k and T cell receptor Vα^a haplotypes: determination with a Vα2-specific monoclonal antibody. Eur J Immunol 22:399-404.

                | Impressum